Abstract:Introduction SCBC is an aggressive subtype of bladder cancer with high metastatic potential and few effective therapies. The defining mutations of neuroendocrine cancers include loss-of-function mutations in p53 and Rb and gain-of-function mutations in driver oncogenes (e.g., MYC). We engineered an orthotopic mouse model of SCBC leveraging these defining mutations to investigate the genetic and epigenetic drivers of SCBC. Methods Lentiviral particles carrying Cre recombinase were produced using Lenti-sgNeo#2/Cre. The bladders of genetically engineered Rb1fl/fl Trp53fl/fl MycLSL/LSL (RPM) mice were transduced with Cre recombinase-expressing lentivirus via transurethral catheterization. Mice were monitored by micro-ultrasound (mUS) and bioluminescent imaging and detected tumors were verified by histology. SCBC morphology was confirmed by hematoxylin and eosin (H&E) staining and synaptophysin immunohistochemistry (IHC) by a genitourinary pathologist. Whole transcriptome (RNAseq) analysis was performed to correlate transcriptomic profile of neuroendocrine mouse tumors to a cohort of human SCBC tumors. Candidate driver genes were prioritized and association with prognosis in human tumors was evaluated (TCGA BLCA, n=417). The function of Forkhead box protein family members coordinately up and down regulated in human and murine SCBC was investigated in human urothelial carcinoma and murine syngeneic cell lines. Results Transurethral catheterization successfully transduced the bladder urothelium without evidence of ectopic (non-urothelial) exposure. RPM mice developed SCBC visible on mUS and bioluminescent imaging within 8-10 weeks. As expected in neuroendocrine tumors, mice developed spontaneous visceral and lung metastases. High grade neuroendocrine morphology and NE markers were confirmed on H&E staining and IHC, respectively, by our genitourinary;pathologist. Western blot analysis confirmed Myc expression and suppression of TP53 and RB1. Transcriptomic profiling of both mouse and human SCBC demonstrated concordant gene expression. Gene expression profiling of mouse neuroendocrine bladder tumors and normal bladder showed increased FOXA2 expression in the tumor and high intratumoral FOXA2 protein expression was confirmed on IHC. TCGA-BLCA analysis showed significantly worse overall survival for patients whose bladder tumors overexpressed FOXA2 (p=0.01). Expression of FOXA2 in human urothelial cancer lines harboring p53 and RB mutations led to increased expression of neuroendocrine markers by immunocytochemistry. Conclusions We developed a novel genetically engineered orthotopic murine model of SCBC which is histologically and morphologically similar to human SCBC. Gene expression profiling of neuroendocrine bladder tumors from these mice suggest FOXA2 may play a role in the initiation and development of the neuroendocrine phenotype. Ongoing work seeks to further characterize the role of FOXA2 in neuroendocrine differentiation and identify other genetic and epigenetic markers that may cooperatively contribute to the development of this aggressive variant of bladder cancer.

Transposon-based oncogene integration in Abcb4(Mdr2)-/- mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis

Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma

Oncogene-Driven Induction of Orthotopic Cholangiocarcinoma in Mice

Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis

Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice.

A novel murine model of combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Molecular profiling reveals potential targets in cholangiocarcinoma

Acquisition of Cholangiocarcinoma Traits During Advanced Hepatocellular Carcinoma Development in Mice

Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma

Characterization of a Syngeneic Orthotopic Model of Cholangiocarcinoma by [18F]FDG-PET/MRI

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice

A NOVEL ORTHOTOPIC MURINE MODEL OF NEUROENDOCRINE BLADDER CANCER: INSIGHTS INTO THE MOLECULAR DRIVERS OF SMALL CELL BLADDER CANCER (SCBC)

Cullin3 deficiency shapes tumor microenvironment and promotes cholangiocarcinoma in liver-specific Smad4/Pten mutant mice

Proteogenomic Characterization of Cholangiocarcinoma

A novel orthotopic murine model of neuroendocrine bladder cancer: Insights into the phenotypic plasticity of small cell bladder cancer (SCBC).

Whole-genome sequencing of 20 cholangiocarcinoma cases reveals unique profiles in patients with cirrhosis and primary sclerosing cholangitis

Abstract 2884: Cancer-associated fibroblasts potentiate subcutaneous tumor growth in a novel bladder cancer mouse model with a genotype dependency

Specific Genomic Alterations and Prognostic Analysis of Perihilar Cholangiocarcinoma and Distal Cholangiocarcinoma.

Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro

Gut Microbial Impact on Colitis and Colitis-Associated Carcinogenesis in a Primary Sclerosing Cholangitis-IBD Model

Abstract 436: An orthotopic murine model of neuroendocrine bladder cancer offers insights into the phenotypic plasticity of small cell bladder cancer (SCBC)